One of the most compelling theories of aging focuses not on what cells stop doing, but on what certain cells never stop doing. Senescent cells — sometimes called zombie cells — are cells that have stopped dividing but refuse to die. They accumulate throughout the body as we age, and mounting evidence suggests they actively damage the tissue around them. A class of compounds called senolytics is designed to selectively eliminate these cells. But how strong is the evidence, and should you be taking fisetin or quercetin?
What Are Senescent Cells and Why Do They Matter?
Cellular senescence is a normal biological process. When a cell sustains damage — from DNA errors, oxidative stress, or other insults — it can enter a permanent growth arrest rather than continuing to divide and potentially become cancerous. In this sense, senescence is a tumor-suppression mechanism, and in young organisms, immune cells (particularly NK cells) efficiently clear senescent cells before they accumulate.
The problem emerges with aging. As immune surveillance weakens and the rate of cellular damage increases, senescent cells begin to accumulate faster than they’re cleared. These lingering zombie cells secrete a cocktail of inflammatory proteins, proteases, and growth factors called the Senescence-Associated Secretory Phenotype (SASP). The SASP damages neighboring healthy cells, promotes chronic inflammation (now called “inflammaging”), and has been linked to tissue dysfunction, metabolic disease, cardiovascular decline, and potentially cancer progression.
Key fact: A 2016 study by the Mayo Clinic found that transplanting as few as 1,000 senescent cells into young, healthy mice was sufficient to cause persistent physical dysfunction and reduced survival — suggesting the damage from even small accumulations of these cells is disproportionately harmful.
Senolytics: The Science of Clearing Zombie Cells
Senolytics are compounds designed to exploit the fact that senescent cells depend on specific anti-apoptotic (cell death-resisting) survival pathways to avoid the death they’d otherwise undergo. By blocking these pathways, senolytics can selectively kill senescent cells while leaving healthy cells largely unaffected — at least in theory.
The most studied senolytic combination is Dasatinib + Quercetin (D+Q), first identified by researchers at the Mayo Clinic in 2015. Dasatinib is an FDA-approved cancer drug (originally for leukemia) that targets certain kinases senescent cells rely on. Quercetin is a plant flavonoid found in onions, apples, and other foods that has independent anti-senescence properties.
Fisetin, another plant flavonoid found in strawberries, apples, and persimmons, has emerged as a particularly promising senolytic due to its apparent potency in animal studies. A 2018 study in EBioMedicine found that fisetin reduced senescent cell burden in multiple tissues of aged mice and extended healthspan.
Human Trial Evidence: Promising but Early
Unlike many longevity interventions, senolytics have actually advanced into human clinical trials — a meaningful step beyond purely preclinical work. Results have been cautiously encouraging:
- A 2019 pilot study (9 patients) found that D+Q reduced senescent cell burden in fat tissue of people with diabetic kidney disease, with some improvements in physical function.
- Studies in idiopathic pulmonary fibrosis (a disease strongly linked to cellular senescence) showed D+Q improved physical performance measures and reduced certain SASP markers.
- Trials in Alzheimer’s disease patients and frailty are ongoing as of 2026.
However, these are small studies, often in disease populations rather than healthy aging individuals. The jump to recommending senolytic supplementation for healthy middle-aged people is not yet supported by the existing data. Most trials have used intermittent (“hit-and-run”) dosing protocols — a few days on, weeks or months off — based on the idea that senolytics don’t need continuous use once the target cells are cleared.
The Supplement Question: Fisetin and Quercetin Without Dasatinib
Many in the consumer longevity space take fisetin and/or quercetin as over-the-counter supplements, without the pharmaceutical component dasatinib. The logic is that they’re natural compounds with favorable safety profiles and some supporting evidence.
The honest assessment is mixed. Fisetin and quercetin are generally safe at reasonable doses. Some studies suggest bioavailability challenges — quercetin in particular is poorly absorbed orally without specific formulations (quercetin phytosome formulations show better absorption). Whether the doses achievable through supplementation are sufficient to meaningfully clear senescent cells in humans remains unproven.
There are also theoretical concerns. Senescent cells, while harmful in excess, are not entirely without function — they play a role in wound healing and embryonic development. Whether aggressive senolytic use could interfere with these processes in some individuals is unknown. Long-term effects of repeated senolytic cycling in humans have not been studied.
Where the Field Is Heading
Senolytic research is one of the most active and credible areas of longevity science. Unlike many longevity interventions that exist only in theory or rodent studies, senolytics have a mechanistically coherent target (the SASP), validated biomarkers to track (p16, p21, inflammatory cytokines), and human trial infrastructure in place.
The next 3-5 years should bring substantially more human data from trials in frailty, cognitive decline, and metabolic disease. Whether this translates into an evidence base for healthy-aging supplementation remains to be seen — but the foundation is more solid than most.
At lifespan.asia, we follow the senolytic research landscape closely, from Mayo Clinic trial updates to emerging natural compound studies. If you’re tracking your biological age and exploring evidence-based interventions, our longevity science coverage is where the clearest signal lives.